Insulet Corp (PODD) Stock AnalysisPODDStock AnalysisInsulet Corp

Insulet Corporation is a medical device company. It is primarily engaged in the development, manufacture and sale of its continuous insulin delivery systems for people with insulin-dependent diabetes. The Omnipod System includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5), the Omnipod DASH Insulin Management System, and the Omnipod Insulin Management System. The Omnipod platform offers continuous insulin delivery that provides various benefits of insulin pump therapy in a way without the need for external tubing required with conventional pumps. The small, lightweight, self-adhesive disposable tubeless Omnipod device (Pod), can be worn in multiple locations, including the abdomen, hip, back of upper arm, upper thigh, or lower back, and delivers insulin into the body through a small flexible tube. It also produces pods for Amgen for use in the Neulasta Onpro kit, a delivery system for Amgen’s Neulasta to help reduce the risk of infection after intense chemotherapy. It operates in the Healthcare sector (SURGICAL & MEDICAL INSTRUMENTS & APPARATUS industry).

Insulet Corp (PODD) is currently not a strong buy. The stock is priced at $145.13, which is significantly lower than the analyst price target of $175, indicating potential upside. However, the stock has seen a year-to-date decline of 48.70% and a 57.92% drop over the past year, which raises concerns about its stability. The RSI is at 48.097, suggesting it is neither overbought nor oversold, while insider buying activity has increased by 409.88%, indicating some confidence from management. The main risk is the recent guidance cut, which implies a slower growth rate than previously expected, with U.S. Omnipod sales growth revised down to 17%-19% from 20%-22%.

17 analysts cover PODD: 10 rate it Buy, 7 Hold and 0 Sell. The average price target is 375.83.